The maker of the first CBD drug isn't stopping with seizure treatment - STAT

WASHINGTON — Justin Gover joined GW Pharmaceuticals (GWPH), a company laser-focused on creating cannabinoid-based medicines, back in 1999, a time when the acronym CBD meant virtually nothing to most Americans, and more than two-thirds of Americans opposed the legalization of marijuana.

Fast forward 20 years and GW is in the middle of a CBD boom.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

| Learn More

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

GET STARTED

MS Mindshift Effort Arrives at Atlanta Area's Owl-...
Scientists report evidence of immune response targ...
 

Comments

No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Guest
Monday, 16 December 2019
 
 

Follow Us on Twitter

Follow Us On Twitter - Image